Phase I/II Study of REGN5668 (MUC16 × CD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16 × CD3)
Details
The main purposes of this study are to:
- Learn about the safety and profile of any side effects from the study drugs and to determine
the highest, safe dose that can be given to participants with ovarian cancer or cancer of the
uterus
- Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus
Eligibility
You can join if...
Inclusion
Is a woman <18 years of age
Is willing and able to comply with clinic visits and study-related procedures and
requirements.
Is willing and able to provide informed consent as specified by health authorities and
institutional guidelines.
Exclusion
Is currently receiving treatment in another study.
Has participated in a study of an investigational agent (except biologics and/or immunotherapy) or an investigational device within 4 weeks of first dose of study drug